Unknown PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT05235542

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

A Phase Ib/II Study of AK104#PD-1 / CTLA-4 Bispecific Antibody# and AK117#Anti-CD47 Antibody# in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Sponsor: Akeso

Conditions Advanced Malignant Tumors

Interventions 5-FU AK104 AK117 Capecitabine tablets Cisplatin Docetaxel Irinotecan Oxaliplatin Paclitaxel

Updated 4 times since 2022 Last updated: Aug 9, 2022 Started: Jul 12, 2022 Primary completion: Mar 31, 2023 Completion: Mar 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05235542, this PHASE1/PHASE2 trial focuses on Advanced Malignant Tumors and remains ongoing. Sponsored by Akeso, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China